Tag Archives: RCKT

Leerink Partners Keeps a Buy Rating on Rocket Pharmaceuticals (RCKT)

In a report issued on September 14, Mani Foroohar from Leerink Partners maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report). The company’s shares closed last Friday at $34.20. According to TipRanks.com, Foroohar is ranked 0 out of

Rocket Pharmaceuticals (RCKT) Gets a Buy Rating from Chardan Capital

In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report). The company’s shares closed last Tuesday at $35.16. According to TipRanks.com, Livshits is a top 100 analyst with an

Leerink Partners Thinks Rocket Pharmaceuticals’ Stock is Going to Recover

In a report issued on August 16, Mani Foroohar from Leerink Partners maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report). The company’s shares closed last Wednesday at $28.66, close to its 52-week low of $21.95. According to

Rocket Pharmaceuticals (RCKT) Gets a Buy Rating from William Blair

William Blair analyst Raju Prasad maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report) today. The company’s shares closed last Monday at $33.63. According to TipRanks.com, Prasad is a 4-star analyst with an average return of 11.5% and

Cowen & Co. Believes Rocket Pharmaceuticals (NASDAQ: RCKT) Won’t Stop Here

In a report issued on August 5, Yaron Werber from Cowen & Co. maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report). The company’s shares closed last Friday at $26.46, close to its 52-week high of $27.73. According

LifeSci Capital Believes Rocket Pharmaceuticals (NASDAQ: RCKT) Won’t Stop Here

In a report released today, Patrick Dolezal from LifeSci Capital maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report), with a price target of $35.00. The company’s shares closed last Wednesday at $25.26, close to its 52-week high